secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001104659-23-059424
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccitech Q1 net loss $18.2M vs $2.6M income; cash $191.3M; positive HBV, HPV data
--------------------------------------------------------------------------------

- Net loss per share $0.48 vs prior year income $0.07; revenue fell to $0.5M from $15.0M due to lower Vaxzevria royalties.
- Cash $191.3M at March 31, 2023, down from $194.4M; cash runway into Q1 2025.
- HBV002 trial met endpoints; meaningful HBsAg reductions; final data to be presented at EASL June 21-24.
- APOLLO HPV trial showed favorable tolerability and T-cell responses; final 12-month data expected Q2 2024.
- Appointed Nadège Pelletier as CSO; COO Chris Ellis to retire Oct 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/0001104659-23-059424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/tm2315505d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer